Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2015-002397-21 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Paediatric long-term safety follow-up clinical trial in maximum 100 children with heart failure due to dilated cardiomyopathy or congenital heart disease, from 1 day to less than 12 years of age at recruitment into the preceding short-term pharmacokinetic (PK)/pharmacodynamic (PD) trials. Pharmacodynamic measurements and renal monitoring in all children after 1 , 4, 7 and 10 months of follow-up; in addition PK assessments as well as acceptability and palatability assessments in children still under enalapril Orodispersible Minitablet (ODMT) treatment.
This clinical trial is one of three clinical trials of the European Commission (FP7)-funded "LENA" (Labeling of Enalapril from Neonates to Adolescents) project: 50 children with heart failure due to dilated cardiomyopathy (LENA-Work Package (WP)08 Trial) and 50 children with heart failure due to congenital heart disease (LENA-WP09 Trial) get treated with an optimal dose of enalapril ODMTs for up to 8 weeks after thorough, individualised titration and get invited to join this 10 months Safety Follow-up Study (LENA-WP10 Trial).
Reliable data on the long-term safety of enalapril in paediatric patients are currently not available. By conducting this long-term Safety Follow-up Trial in children who received or still receive enalapril Orodispersible Minitablets at the end of the 8-weeks PK/PD LENA-Work Package (WP)08 (children with heart failure due to dilated cardiomyopathy) and LENA-WP09 (children with heart failure due to congenital heart disease) Trials using sensitive and highly specific assay methodology, it will be possible to add to the generation of reliable PK and PD data in the whole paediatric age range from birth to 12 years. In addition, this follow-up study will allow to systematically collect follow-up information over 10 more months, so in total 12 months, in paediatric patients under long-term enalapril ODMT treatment and in paediatric patients who had received at least 3 days of ODMT treatment but then stopped for any reason.
The End-of-study Visit of the WP08 and WP09 Trials is also the First Visit of the Follow-up Study. Further Visits occur after 1 month, 4 months, 7 months and 10 months.
At each Visit blood pressure and renal monitoring as well as pharmacodynamic parameters and adverse events are assessed. In children under ongoing enalapril ODMT treatment, single PK sampling as well as acceptability and palatability assessments are made at each Visit.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Enalapril Orodispersible Minitablets | Experimental | Individually adapted dose of enalapril consisting of 1 to maximum 4 enalapril ODMTs of 0.25 mg and/or 1 mg and/or other prescribed treatment of heart failure. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Enalapril Orodispersible Minitablet | Drug | Weight-dependent long-term treatment scheme with enalapril ODMTs of 0.25 and/or 1 mg strength |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with Adverse Reactions | Adverse Reaction definition according to European Directive 2001/20/EC, assessed at each Visit concerning intensity and causality | up to month 10 |
| Measure | Description | Time Frame |
|---|---|---|
| Blood pressure | Measurement pre-dose after 5 minutes at rest at every Visit up to end of treatment at Month 10 | At every Visit: (day 0, month 1, 4, 7, 10) |
| Renin | Renin to assess the Renin-angiotensin-aldosterone system (RAAS) measured at every Visit up to end of treatment at Month 10 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Patients who have been enrolled and treated in the WP08 or WP09 Trials have fulfilled the respective in- and exclusion criteria of those protocols. As it is the aim of this Follow-up Study to observe the safety of all patients exposed to enalapril ODMT treatment, no additional exclusion criteria are defined in this protocol. However, adapted to the health situation of the patient, the investigator will decide whether planned study activities can be performed.
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Stephanie Laeer, Prof,MD,PhD | Contact | +49 211 8110740 | Stephanie.Laeer@uni-duesseldorf.de | |
| Ingrid Klingmann, MD,PhD | Contact | +32 2 784 3693 | iklingmann@pharmaplex.be |
| Name | Affiliation | Role |
|---|---|---|
| Saskia N. de Wildt, MD,PhD | Sophia Children's Hospital, Erasmus MC | Study Chair |
| Michiel Dalinghaus, MD,PhD | Sophia Children's Hospital, Erasmus MC | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medical University of Vienna | Vienna | 1090 | Austria |
Serious Adverse Event information
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Pre-dose at each Visit: (day 0, month 1, 4, 7, 10) |
| Angiotensin 1 | Angiotensin 1to assess the Renin-angiotensin-aldosterone system (RAAS) measured at every Visit up to end of treatment at Month 10 | Pre-dose at each Visit: (day 0, month 1, 4, 7, 10) |
| Aldosterone | Aldosterone to assess the Renin-angiotensin-aldosterone system (RAAS) measured at every Visit up to end of treatment at Month 10 | Pre-dose at each Visit: (day 0, month 1, 4, 7, 10) |
| Plasma Renin Activity | Plasma renin activity to assess the Renin-angiotensin-aldosterone system (RAAS) measured at every Visit up to end of treatment at Month 10 | Pre-dose at each Visit: (day 0, month 1, 4, 7, 10) |
| Creatinine | Creatinine for renal monitoring measured at every Visit up to end of treatment at Month 10 | Pre-dose at each Visit: (day 0, month 1, 4, 7, 10) |
| Urea nitrogen | Urea nitrogen for renal monitoring measured at every Visit up to end of treatment at Month 10 | Pre-dose at each Visit: (day 0, month 1, 4, 7, 10) |
| Serum potassium | Serum potassium for renal monitoring measured at every Visit up to end of treatment at Month 10 | Pre-dose at each Visit: (day 0, month 1, 4, 7, 10) |
| Brain-Natriuretic-Peptides (BNP) | BNP measured at every visit up to end of treatment at Month 10 to observe disease severity | Pre-dose at each Visit: (day 0, month 1, 4, 7, 10) |
| Micro-albuminuria | Measurement of micro-albuminuria for renal monitoring measured at every Visit up to end of treatment at Month 10 | Pre-dose at each Visit: (day 0, month 1, 4, 7, 10) |
| Clinical haematology | Assessment at First and Last Study Visit at the end of treatment at Month 10 | Day 0 and Month 10 |
| ECG | Assessment at First and Last Study Visit at the end of treatment at Month 10 | Day 0 and Month 10 |
| Plasma concentration of enalapril and its active metabolite enalaprilat under long-term treatment | At each Visit in children under enalapril ODMT treatment a single blood sample will be collected to measure the enalapril and enalaprilat plasma levels during long-term treatment; population-kinetic investigation | Pre-dose at each Visit: (day 0, month 1, 4, 7, 10) |
| Acceptability assessment of enalapril ODMTs | Acceptability assessment at each Visit up to end of treatment at 10 months in children under enalapril ODMT treatment according to an age-appropriate scale | At each Visit: (day 0, month 1, 4, 7, 10) |
| Palatability assessment of enalapril ODMTs | Palatability assessment at each Visit up to end of treatment at Month 10 in children under enalapril ODMT treatment according to an age-appropriate scale | At each Visit: (day 0, month 1, 4, 7, 10) |
| J.M.P. J. Breur, MD,PhD |
| Wilhelmina Children's Hospital, University Medical Center Utrecht |
| Principal Investigator |
| Ida Jovanovic, Prof,MD,PhD | Univerzitetska Dečja Klinika Belgrade | Principal Investigator |
| Christoph Male, Prof,MD,PhD | Medical University of Vienna | Principal Investigator |
| Michael Burch, Prof,MD,PhD | Great Ormond Street Hospital for Children NHS Trust London | Principal Investigator |
| András Szatmári, Prof,MD,PhD | Hungarian Paediatric Heart Centre, Göttsegen Gyorgy Hungarian Institute of Cardiology | Principal Investigator |
| Hungarian Paediatric Heart Centre,Göttsegen Gyorgy Hungarian Institute of Cardiology | Budapest | 1095 | Hungary |
|
| Sophia Children's Hospital Erasmus MC | Rotterdam | 3015 CN | Netherlands |
|
| Wilhelmina Children's Hospital, University Medical Center Utrecht | Utrecht | 3584 CX | Netherlands |
|
| Univerzitetska Dečja Klinika | Belgrade | 11129 | Serbia |
|
| Great Ormond Street Hospital for Children NHS Trust | London | WC1N 3JH | United Kingdom |
|
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| D002311 | Cardiomyopathy, Dilated |
| D006330 | Heart Defects, Congenital |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D006332 | Cardiomegaly |
| D009202 | Cardiomyopathies |
| D000083083 | Laminopathies |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D018376 | Cardiovascular Abnormalities |
| D000013 | Congenital Abnormalities |
Not provided
Not provided